Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients (REGOMAIN)

This is a randomized, double-blinded, 2 arms study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or first relapse. In the first arm, patients will be treated with regorafenib + best supportive care (BSC) for a maximum of 12 months as maintenance therapy …

cancer chemotherapy
glomerular filtration rate
cancer
neutrophil count
kidney function tests
  • 0 views
  • 27 May, 2022
  • 3 locations
Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.

The purpose of this trial is to investigate whether previously reported benefit of Tranexamic acid in pediatric orthopedic surgeries could be recapitulated in bone tumor surgeries or not through a double blinded randomized controlled trial done in children cancer hospital 57357.

cancer chemotherapy
cancer
  • 0 views
  • 04 Oct, 2022
  • 1 location
Regorafenib in Patients With Refractory Primary Bone Tumors (Regbone)

The aim of the project is to improve treatment outcomes in patients with primary malignant bone tumors, refractory to standard therapy, by increasing the availability of advanced therapy, as well as to develop treatment options using advanced molecular diagnostics for patients who have not responded to the standard therapeutic regimen, …

  • 0 views
  • 07 Oct, 2022
  • 1 location
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE)

INDICATION Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone, intermediate or high-grade chondrosarcomas and chordomas and

cancer chemotherapy
glomerular filtration rate
immunomodulators
sarcoma of bone
cancer
  • 42 views
  • 27 Apr, 2022
  • 18 locations
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

Two cycles of neoadjuvant three-component chemotherapy according to the MAP prototoc: Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. Methotrexate 12 g / m2 at 28 and 35 …

g-csf
cancer chemotherapy
neutrophil count
doxorubicin
filgrastim
  • 0 views
  • 10 Mar, 2022
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA)

This is a randomized, double-blinded, 2 arms study concerning patients with bone sarcoma after the first line therapy. In the first arm, patients will be treated with regorafenib for a maximum of 12 months as maintenance therapy after first line therapy, whereas in the second arm, patients will be treated …

adriamycin
cancer chemotherapy
glomerular filtration rate
ifosfamide
immunomodulators
  • 1 views
  • 04 Oct, 2022
  • 5 locations
3D Printed Implants for the Defect Reconstruction in Patients With Chest Wall Tumors

A patient with a tumor lesion of the chest wall undergoes CT scan with a step width of less than 1 mm, then engineers design an individual model to replace the defect. Using a 3D printer, a model is made based on titanium alloy powder. Preoperative preparation takes an average …

  • 0 views
  • 07 Mar, 2022
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

This study will enroll patients who have a diagnosis of locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's sarcoma) from any site.

adriamycin
cancer chemotherapy
vincristine
ewing's sarcoma
measurable disease
  • 0 views
  • 26 Mar, 2022
  • 1 location
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back …

cancer chemotherapy
undifferentiated pleomorphic sarcoma
adjuvant chemotherapy
sarcoma of bone
cancer
  • 325 views
  • 04 Oct, 2022
  • 1 location
  • 92 views
  • 27 Oct, 2022
  • 33 locations